There were significant differences between combined therapy and ticagrelor therapy for sex, age, smoking, previous MI, previous PCI, heart failure history, hypertension, peripheral vascular disease (PVD) history, chronic obstructive pulmonary disease, renal failure history, type of ACS, SBP, Killip class, cardiogenic shock, heart failure, sudden cardiac arrest, PCI, culprit vessel, stent implantation, statins, β-blocker, ACEI, ARB, aldosterone receptor antagonist, warfarin, anticoagulant drug use, hemoglobin, serum creatinine, FBG, INR, and TC. This evidence concerns the gene NR3C2 and Shock.